Cannabidiol-enriched cannabis extraction product in Parkinson's disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital.

Objectives: The objective of this study was to assess cannabidiol-enriched cannabis extraction product (CBDEP) efficacy in patients with Parkinson's disease (PD).

Materials And Methods: Forty patients with PD were randomly assigned to the sublingual CBDEP ( = 20) or placebo ( = 20) group. All patients were prescribed a low initial dose with gradual titration within 2 weeks based on individual response - including side effects - followed by 6 weeks of stable dosing.